Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Polyphor AG (POLN) CHF2

Sell:7.33 CHF Buy:7.44 CHF Change: 0.11 CHF (1.50%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:7.33 CHF
Buy:7.44 CHF
Change: 0.11 CHF (1.50%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:7.33 CHF
Buy:7.44 CHF
Change: 0.11 CHF (1.50%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Polyphor AG is a Switzerland-based company, which is engaged in the development of novel antibiotics and other efficacious therapies. The Company's medicines pipeline includes Murepavadin (POL7080), a novel class of specific outer membrane protein targeting antibiotic to treat resistant Pseudomonas infections; the Outer Membrane Protein Targeting Antibiotics (OMPTA), which provides treatment options to treat infections caused by Gram-negative bacteria; POL6014 is inhaled elastase inhibitor for the treatment of Cystic Fibrosis and other neutrophilic lung diseases, as well as Balixafortide (POL6326) is a blocker of tumor growth and metastasis. The Company develops Macrocycle discovery platform, which includes library consisted of over 50,000 single, untagged, individually purified peptidic and non-peptidic macrocycles readily amenable to all screening formats, including binding, enzymatic, cellular, pathway and phenotypical.

Contact details

Address:
Hegenheimermattweg 125
ALLSCHWIL
4123
Switzerland
Telephone:
+41 (61) 5671600
Website:
https://www.polyphor.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
POLN
ISIN:
CH0106213793
Market cap:
81.09 million CHF
Shares in issue:
11.06 million
Sector:
Biotechnology
Exchange:
SIX Swiss Exchange
Country:
Switzerland
Currency:
Swiss Franc
Indices:
Swiss All Share Index

Key personnel

  • Kuno Sommer
    Chairman of the Board
  • Giacomo Di Nepi
    Chief Executive Officer, Member of the Management Board
  • Andreas Wallnoefer
    Vice Chairman of the Board
  • Kalina Scott
    Chief Financial Officer, Member of the Management Board
  • Franziska Mueller
    Member of the Management Board, Head of Human Resources
  • Daniel Obrecht
    Chief Scientific Officer, Member of the Management Board
  • Helmut Kessmann
    Member of the Management Board, Head of Business Development Pharma
  • Gokhan Batur
    Member of the Management Board, Chief Commercial Officer
  • Frank Weber
    Chief Medical and Development Officer, Member of the Management Board

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.